--- title: "U.S. Stock Market Midday Update: Novo Nordisk's stock price rises by 13.53%, with stock buybacks and market competition intertwining to affect prospects" type: "News" locale: "en" url: "https://longbridge.com/en/news/280516061.md" description: "BGM rose 13.53%; Terns Pharmaceuticals rose 5.73%, with a transaction volume of USD 3.87 billion; Eli Lilly rose 1.53%, with a transaction volume of USD 1.054 billion; Johnson & Johnson rose 2.08%, with a transaction volume of USD 813 million; Merck rose 2.36%, with a market value of USD 294.5 billion" datetime: "2026-03-25T18:43:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280516061.md) - [en](https://longbridge.com/en/news/280516061.md) - [zh-HK](https://longbridge.com/zh-HK/news/280516061.md) --- # U.S. Stock Market Midday Update: Novo Nordisk's stock price rises by 13.53%, with stock buybacks and market competition intertwining to affect prospects **U.S. Stock Market Midday Update** BGM rose 13.53%, with increased trading volume. Based on recent news, 1. On March 20, Novo Nordisk's patent for semaglutide in China expired, leading to the imminent launch of generic drugs. The expiration of the patent means increased market competition, which may affect the company's market share in China. 2. On March 23, Novo Nordisk announced a stock repurchase plan worth 1.5 billion Danish kroner. This move may boost investor confidence and support the stock price. 3. On March 20, Novo Nordisk met with Chinese government officials to discuss investment and cooperation in China. Such high-level exchanges help the company’s long-term development in the Chinese market. The pharmaceutical industry is facing intensified competition, with clear market segmentation. **Stocks with High Trading Volume in the Industry** Terns Pharmaceuticals rose 5.73%. Based on recent key news: 1. On March 25, Merck announced it would acquire Terns Pharmaceuticals for $53 per share, totaling approximately $6.7 billion. This news drove Terns' stock price up by 5.3%. Source: Financial Associated Press 2. On March 25, Terns' core drug TERN-701 showed a 75% primary molecular response rate in early trials, and the market is optimistic about its prospects. Source: Financial Associated Press 3. On March 25, analysts estimated that TERN-701's annual peak sales could reach $2.3 billion, further enhancing investor confidence. Source: Financial Associated Press The pharmaceutical industry is active in mergers and acquisitions, with the market focusing on new drug development. Eli Lilly rose 1.53%, with increased trading volume. Based on recent key news: 1. On March 25, the strategic cooperation agreement between Innovent Biologics and Eli Lilly took effect, promoting new drug development in oncology and immunology. Innovent Biologics will receive a $350 million upfront payment and is eligible for up to $8.85 billion in milestone payments. This cooperation has strengthened market confidence in Eli Lilly's future growth, driving the stock price up. Source: Zhitong Finance 2. On March 23, Minister of Commerce Wang Wentao met with Eli Lilly's CEO to discuss Sino-U.S. economic and trade relations and Eli Lilly's business in China. Eli Lilly plans to invest an additional $3 billion in China over the next decade to support the Healthy China initiative. This news boosted investor confidence and drove the stock price up. Source: Economic Information Daily 3. On March 24, Eli Lilly announced that its diabetes drug significantly reduced blood sugar levels in clinical trials, accompanied by weight loss. This positive clinical result has raised market expectations for the company's product line, further driving the stock price up. Source: Benzinga Pro The pharmaceutical industry has broad prospects in the Chinese market, attracting investor attention. Johnson & Johnson rose 2.08%, with increased trading volume. Based on recent key news: 1. On March 25, market rumors suggested that Johnson & Johnson might acquire the French nanobiotechnology company Nanobiotix, leading to a nearly 9% increase in Nanobiotix's stock price. Although Nanobiotix denied ongoing acquisition negotiations, the market's interest in Johnson & Johnson's potential acquisition has still attracted investor attention 2. On March 25, Johnson & Johnson's partnership with Nanobiotix is believed to potentially bring greater global equity and pricing power, which has boosted market confidence in Johnson & Johnson's future growth potential. 3. On March 26, Nanobiotix clarified that it is not in acquisition negotiations, attempting to stabilize investor sentiment, but market confidence in its innovation capabilities remains high. The biotechnology sector has performed strongly recently, with significant capital inflows. **Stocks Ranked Among the Top by Market Capitalization in the Industry** Merck rose 2.36%. Based on recent news, 1. On March 25, Merck announced the acquisition of Terns Pharmaceuticals for $53 per share in cash, with a total equity value of approximately $6.7 billion. Following this announcement, Merck's stock price rose 0.4% in pre-market trading. 2. On March 25, the transaction is expected to be accounted for as an asset acquisition and is set to be completed in the second quarter of 2026, resulting in approximately $5.8 billion in expenses, or about $2.35 per share of MRK, impacting both GAAP and non-GAAP results for the second quarter and full year of 2026. 3. On March 25, through this acquisition, Merck will gain rights to Terns Pharmaceuticals' investigational drug TERN-701, which is used for the treatment of chronic myeloid leukemia. The pharmaceutical industry has seen frequent merger and acquisition activities recently, intensifying market competition ### Related Stocks - [BGM.US](https://longbridge.com/en/quote/BGM.US.md) ## Related News & Research - [Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement](https://longbridge.com/en/news/289314395.md) - [Centessa Shareholders Approve Eli Lilly Acquisition Scheme](https://longbridge.com/en/news/289645940.md) - [Jim Cramer Sees Eli Lilly (LLY) Delivering 'Knockout Punch' to Competitors](https://longbridge.com/en/news/288886593.md) - [Drugmakers will not be exempt from cost cuts, says German health minister](https://longbridge.com/en/news/289621266.md) - [Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake](https://longbridge.com/en/news/289517633.md)